ストックスクリーナーアプリを入手
1.38
0.72%
-0.01
前日終値:
$1.39
開ける：
$1.35
24時間の取引高:
141.52K
Relative Volume:
0.92
時価総額：
$24.59M
収益：
-
当期純損益:
$-8.29M
株価収益率:
-1.9714
EPS:
-0.7
ネットキャッシュフロー:
$-6.47M
1週間 パフォーマンス:
+12.20%
1か月 パフォーマンス:
-6.12%
6か月 パフォーマンス:
-8.00%
1年 パフォーマンス:
-21.59%
1日の値動き範囲:
$1.35
$1.4382
1週間の範囲:
$1.32
$1.44
52週間の値動き範囲:
$0.94
$2.55
NanoViricides Inc Stock (NNVC) Company Profile
NNVC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.38 | 24.59M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2015-02-11 | 開始されました | Midtown Partners | Strong Buy |
NanoViricides Inc (NNVC) 最新ニュース
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan - Knoxville News Sentinel
NanoViricides' NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu - citybuzz -
Small cap wrap: Fineqia, NanoViricides, Standard Uranium... - Proactive Investors
NanoViricides touts antiviral NV-387 as tool against new COVID variant - Proactive financial news
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in AfricaPhase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu - The Columbus Dispatch
NanoViricides Advances Measles Drug Program as Global Outbreaks Rise - citybuzz -
NanoViricides Measles Drug Development Animal Study is Imminent - Akron Beacon Journal
Small cap wrap: NanoViricides, New Era Helium, Charbone Hydrogen, Voyageur Pharmaceuticals... - Proactive Investors
NanoViricides commissions animal study of broad-spectrum antiviral for measles - Proactive Investors
NanoViricides (NNVC) Advances Measles Drug Development | NNVC St - GuruFocus
Breakthrough Measles Drug Enters Critical Testing Phase as Global Cases Surge 10X - Stock Titan
Nanoviricides (NNVC) To Unveil 'Escape-Proof' Antiviral Platform At Major Biotech Convention - MENAFN.com
NanoViricides (NNVC) to Unveil 'Escape-Proof' Antiviral Platform at Major Biotech Convention - openPR.com
Gold Is Bullish, But Be Aware Of Deeper Intraday Pullback; Elliott Wave Intraday Analysis - The Globe and Mail
NanoViricides (NNVC) to Unveil ‘Escape-Proof’ Antiviral Platform at Major Biotech Convention - The Globe and Mail
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 - Lohud
NanoViricides to Showcase Breakthrough Antiviral Platform at BIO International Convention - citybuzz -
Hudbay Receives TSX Approval for Normal Course Issuer Bid - The Globe and Mail
NanoViricides to present at BIO International Convention 2025 in Boston - Proactive financial news
NanoViricides president backs FDA's targeted COVID booster policy shift - Proactive financial news
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan - ACCESS Newswire
Small cap wrap: NanoViricides, Trust Stamp, NextSource, StickIt... - Proactive financial news
NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox - Proactive Investors
NanoViricides: MPox ethics approval enables Phase 2 application - Proactive Investors
NanoViricides: Fiscal Q3 Earnings Snapshot - Huron Daily Tribune
Small cap wrap: atai, Black Swan Graphene, TNR Gold, NanoViricides... - Proactive financial news
NanoViricides progresses antiviral portfolio as measles and MPox threats rise - Proactive financial news
Measles Cases Are Increasing Globally; MPox Continues to Be a ThreatBroad-Spectrum Antiviral Drug Could Be the Solution - The Derrick
AMAT Likely to Beat Q2 Earnings Estimates: How to Play the Stock - The Globe and Mail
Small cap wrap: NanoViricides, Alvopetro, Polarean... - Proactive financial news
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC - Proactive financial news
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo - The Derrick
Renaissance Technologies LLC Buys 30,800 Shares of NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides Inc (NNVC) 財務データ
収益
当期純利益
現金流量
EPS
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):